NewSquare Capital LLC Has $7.28 Million Position in Amgen Inc. $AMGN

NewSquare Capital LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,371 shares of the medical research company’s stock after acquiring an additional 1,334 shares during the quarter. NewSquare Capital LLC’s holdings in Amgen were worth $7,284,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Brighton Jones LLC boosted its stake in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the period. Abel Hall LLC bought a new stake in Amgen in the 1st quarter valued at $232,000. Envestnet Asset Management Inc. boosted its stake in Amgen by 12.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,419,605 shares of the medical research company’s stock valued at $442,278,000 after purchasing an additional 152,514 shares during the period. TD Private Client Wealth LLC boosted its stake in Amgen by 6.5% in the 1st quarter. TD Private Client Wealth LLC now owns 24,113 shares of the medical research company’s stock valued at $7,512,000 after purchasing an additional 1,475 shares during the period. Finally, Callan Capital LLC boosted its stake in Amgen by 8.2% in the 1st quarter. Callan Capital LLC now owns 3,270 shares of the medical research company’s stock valued at $1,019,000 after purchasing an additional 247 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of AMGN stock opened at $296.30 on Tuesday. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88. The company has a market cap of $159.52 billion, a P/E ratio of 24.23, a P/E/G ratio of 2.61 and a beta of 0.49. The business has a fifty day simple moving average of $287.91 and a 200 day simple moving average of $287.63.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the prior year, the company earned $4.97 EPS. Amgen’s revenue for the quarter was up 9.4% on a year-over-year basis. On average, sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio (DPR) is 77.84%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.76% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. UBS Group reduced their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Citigroup upped their target price on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. Weiss Ratings upgraded Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Morgan Stanley upped their target price on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $300.94.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.